Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Buy
60
VRTX Quote, Financials, Valuation and Earnings
Last price:
$463.90
Seasonality move
:
0.93%
Day range:
$463.39 - $475.33
52-week range:
$362.50 - $519.68
Dividend yield:
0%
P/E ratio:
32.69x
P/S ratio:
10.24x
P/B ratio:
6.80x
Volume:
1.7M
Avg. volume:
1.3M
1-year change:
12.56%
Market cap:
$117.7B
Revenue:
$11B
EPS (TTM):
$14.19
Analysts' Opinion
-
Consensus RatingVertex Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 19 Buy ratings, 8 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $500.40, Vertex Pharmaceuticals, Inc. has an estimated upside of 7.88% from its current price of $463.86.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $330.00 representing 28.86% downside risk from its current price of $463.86.
Fair Value
-
According to the consensus of 28 analysts, Vertex Pharmaceuticals, Inc. has 7.88% upside to fair value with a price target of $500.40 per share.
VRTX vs. S&P 500
-
Over the past 5 trading days, Vertex Pharmaceuticals, Inc. has overperformed the S&P 500 by 1.01% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Vertex Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Vertex Pharmaceuticals, Inc. has grown year-over-year revenues for 30 quarters straight. In the most recent quarter Vertex Pharmaceuticals, Inc. reported revenues of $3.1B.
Earnings Growth
-
Vertex Pharmaceuticals, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Vertex Pharmaceuticals, Inc. reported earnings per share of $4.20.
Enterprise value:
113.2B
EV / Invested capital:
--
Price / LTM sales:
10.24x
EV / EBIT:
25.00x
EV / Revenue:
9.65x
PEG ratio (5yr expected):
1.15x
EV / Free cash flow:
33.93x
Price / Operating cash flow:
36.02x
Enterprise value / EBITDA:
23.95x
Gross Profit (TTM):
$10.1B
Return On Assets:
15.69%
Net Income Margin (TTM):
31.32%
Return On Equity:
22.13%
Return On Invested Capital:
20.08%
Operating Margin:
41.02%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $9.6B | $10.6B | $11.7B | $2.8B | $3.1B | |
| Gross Profit | $8.4B | $9.1B | $10.1B | $2.4B | $2.7B | |
| Operating Income | $3.8B | -$307.8M | $4.5B | $1.1B | $1.3B | |
| EBITDA | $4B | -$88.1M | $4.7B | $1.2B | $1.3B | |
| Diluted EPS | $13.32 | -$1.99 | $14.19 | $4.01 | $4.20 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $8.9B | $12.3B | $14.7B | $9.8B | $10.6B | |
| Total Assets | $12.6B | $16.7B | $21.7B | $22.2B | $24.9B | |
| Current Liabilities | $1.9B | $2.6B | $3.6B | $4B | $4.5B | |
| Total Liabilities | $3.1B | $3.7B | $5.2B | $6.6B | $7.5B | |
| Total Equity | $9.5B | $13B | $16.5B | $15.6B | $17.3B | |
| Total Debt | $876.8M | $824.6M | $744.7M | $1.7B | $1.8B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $4.4B | -$842.6M | $3.7B | $1.4B | $1.2B | |
| Cash From Investing | -$2.1B | -$3.8B | -$1.5B | -$348M | -$117M | |
| Cash From Financing | -$402.2M | -$1.2B | -$2.6B | -$387.5M | -$1.2B | |
| Free Cash Flow | $4.2B | -$1.4B | $3.3B | $1.3B | $1.1B | |
VRTX
Sector
Market Cap
$117.7B
$28.1M
Price % of 52-Week High
89.26%
51.87%
Dividend Yield
0%
0%
Shareholder Yield
2.03%
-1.59%
1-Year Price Total Return
12.56%
-17.31%
Beta (5-Year)
0.310
0.495
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$461.76
200-day SMA
Buy
Level
$438.36
Bollinger Bands (100)
Buy
Level
395.12 - 446.82
Chaikin Money Flow
Buy
Level
472.5M
20-day SMA
Buy
Level
$458.05
Relative Strength Index (RSI14)
Buy
Level
55.66
ADX Line
Buy
Level
19.39
Williams %R
Neutral
Level
-53.2883
50-day SMA
Buy
Level
$441.76
MACD (12, 26)
Buy
Level
7.32
25-day Aroon Oscillator
Buy
Level
72
On Balance Volume
Neutral
Level
232.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (11.287)
Buy
CA Score
(Annual)
Level (1.6564)
Buy
Beneish M-Score
(Annual)
Level (-2.4334)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-6.3426)
Sell
Piotroski F Score
(Annual)
Level (2)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Stock Forecast FAQ
In the current month, VRTX has received 19 Buy ratings 8 Hold ratings, and 1 Sell ratings. The VRTX average analyst price target in the past 3 months is $500.40.
-
Where Will Vertex Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Vertex Pharmaceuticals, Inc. share price will rise to $500.40 per share over the next 12 months.
-
What Do Analysts Say About Vertex Pharmaceuticals, Inc.?
Analysts are divided on their view about Vertex Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Vertex Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $330.00.
-
What Is Vertex Pharmaceuticals, Inc.'s Price Target?
The price target for Vertex Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $500.40 according to 28 Wall Street analysts, 19 of them rate the stock a Buy, 1 rates the stock a Sell, and 8 analysts rate the stock a Hold.
-
Is VRTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Vertex Pharmaceuticals, Inc. is a Buy. 19 of 28 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of VRTX?
You can purchase shares of Vertex Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Vertex Pharmaceuticals, Inc. shares.
-
What Is The Vertex Pharmaceuticals, Inc. Share Price Today?
Vertex Pharmaceuticals, Inc. was last trading at $463.90 per share. This represents the most recent stock quote for Vertex Pharmaceuticals, Inc.. Yesterday, Vertex Pharmaceuticals, Inc. closed at $463.86 per share.
-
How To Buy Vertex Pharmaceuticals, Inc. Stock Online?
In order to purchase Vertex Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get VRTX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
VRTX
Sector
P/E ratio
32.69x
24.20x
PEG ratio
1.15x
-0.01x
P/B ratio
6.80x
1.84x
Price / LTM sales
10.24x
1.60x
Growth Metrics
VRTX
Sector
Revenue growth
12.27%
4.51%
Earnings growth
4.95%
10.7%
Revenue (5-year growth)
21.61%
6.45%
Earnings forecast
$5.14
-$0.19
Profitability
VRTX
Sector
Profitability FY 2024
$9.5B
$3.5M
Return on invested capital
20.08%
-32.3%
Return on assets
15.69%
-28.57%
Return on equity
22.13%
-38.09%
Earnings Date
Last Earnings Date
Nov
3
Next Earnings Date
Feb
9
Estimated Next Earnings Date
Feb
2
Balance Sheet
VRTX
Sector
Total cash
$6.3B
$26M
Short term investments
$1.5B
$25.7M
Total assets
$23.1B
$76.4M
Long term debt
$1.8B
$3.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
